VANCOUVER, March 29, 2017 /CNW/ - Despite advances in cancer research and treatment, cancer is threatening society now more than ever in recorded history. To better appreciate the magnitude of this crisis, in 2013, an estimated 8.2 million cancer deaths occurred worldwide (100,000 of them being children). By 2030, this number will double to 17 million (Reference). In Canada, it is the leading cause of death across all provinces. (Reference). With few exceptions, cancers that are deemed inoperable or have spread to other organs (metastasized) remain incurable and lethal. Unaware of this, the great majority of cancer patients in the US with inoperable or metastatic cancers accept to endure the side effects of traditional chemotherapy without seeking out other treatment options. Unfortunately, these patients eventually succumb to their disease (Reference).
Dr. Frank Arguello, M.D., a former Assistant Prof. of Oncology, Pediatrics Hematology, and Oncology at the University of Rochester School of Medicine & Dentistry and a former Senior Scientist at the Division of Cancer Treatment, Drug Discovery, Research and Development. National Cancer Institute, National Institutes of Health in Maryland, is the current Director of the Atavistic Chemotherapy Clinical Trial where, since 2011, has been researching, evaluating and implementing a new, revolutionary approach to cancer treatment known as "Atavistic Chemotherapy". The results of which are likely to change the way we understand and treat cancer in the world moving forward.
Armed with this new, non-toxic and effective treatment option, Dr. Arguello would like to invite those currently struggling with a cancer diagnosis, local oncologists or concerned family members and friends to attend a free one-hour conference at 2pm on Saturday, April 15th, 2017 at UBC Robson Square where he will share his research, findings and patient success stories and discuss trial participation options.
To register to attend visit https://goo.gl/Jw6vFd. Please note, space is limited. Doors will open at 1:00 PM for light refreshments.
When asked as to the reason Dr. Arguello is hosting this informative conference in Vancouver, he said "In the US, doctors and hospitals have a strong financial incentive to treat cancer patients who hold medical insurance, even those with inoperable and metastatic cancers, and for whom chemotherapy is known to be of limited benefit, if any. In Canada however, doctors do not have any financial incentive to treat patients for whom traditional chemotherapy has not historically shown benefit. So, they tend to be honest about the patient's prognosis, and in doing so, the patient can take control of the options that are in their best interest. In fact, the great majority of cancer patients enrolled in my clinical trial are Canadians."
For more information on Atavistic Chemotherapy, the conference and Dr. Arguello visit www.AtavisticChemotherapy.com
SOURCE Vancouver Cancer Conference 2017
For further information: Media Contact: Alyssa Brownsmith, Managing Director, Alyssa Brownsmith Events, email@example.com, 604.729.7626